
AACR 2025: Off-the-Shelf CAR NK Therapy SENTI-202 Shows Potential for Complete Remission in R/R AML
Interim results from the phase 1 SENTI-202-101 clinical trial (NCT06325748) investigating SENTI-202 (Senti Biosciences), a first-in-class off-the-shelf chimeric antigen receptor natural killer (CAR NK) cell therapy, were presented at the 2025 American …